Even though KRAS-mutants (specifically KRASp.A146T and KRASp.A146V) were expressed at much lower levels compared to KRASWT following lentiviral transfection of JJN3 and OPM2 cells, anincrease or at least comparable levels of activated MEK and ERK (p-MEK and p-ERK) were observed upon the overexpression of KRASG12A/A146T/A146V compared to KRASWTfor both MM cell lines tested (Figure 5A, Figure S4A, Table S4A). The gene discussed is KRAS; the disease is Miyoshi myopathy.